FBI Director Kash Patel said the bureau has revived an aggressive campaign against Chinese espionage and illicit research activity, warning that prior investigations into dangerous biolabs and academic infiltration were mishandled under the Biden administration.
By yourNEWS Media Newsroom
FBI Director Kash Patel said Friday that the bureau has resumed a broad and aggressive counterintelligence offensive against China and the Chinese Communist Party, reversing what he described as a sidelining of such efforts during the Biden administration and raising concerns that earlier leadership may have concealed critical information about dangerous biolabs operating on U.S. soil.
In an interview with Just the News, Patel said the renewed focus has already produced tangible results, including a reported 40 percent increase in arrests tied to Chinese espionage during the first year of the second Trump administration.
“This FBI, under this leadership, has prioritized the threat against it by the CCP against us, and we’ve taken swift action,” Patel said, describing a reprioritization of what he called a dynamic threat landscape. He said the bureau, working with the Department of Justice and the attorney general, has focused on disrupting criminal activity linked to the CCP.
Patel also raised alarms about illegal biolabs discovered in recent years, including a makeshift facility uncovered in Reedley, California, in 2023 and another hazardous laboratory raided by the FBI and local authorities in a Las Vegas garage over the weekend. According to court filings, law enforcement officials, and members of Congress, both labs are tied to a Chinese national currently awaiting trial on charges including fraud, false statements, and adulteration of medical devices.
Separate findings by the American Accountability Foundation have alleged that at least 20 Chinese scientists working in U.S. academia and advanced research labs appear to be members of the CCP or affiliated with projects aimed at stealing U.S. technology or supporting entities connected to China’s military and defense sector.
Those research ties have heightened concern among federal health officials. Jay Bhattacharya, director of the National Institutes of Health, said the discoveries in California and Nevada underscore the risks posed by unregulated biological research.
“When you do research like this, potentially in an environment where there’s very little biosecurity, you’re posing hazards to everyone around you,” Bhattacharya said. “And the fact is these were completely flying under the radar screen.” He added that better systems are needed to detect and prevent such labs from operating undetected, warning that the agents reportedly involved were “very, very dangerous.”
Patel said the FBI is committed to transparency in the ongoing Las Vegas investigation and suggested that the public may have been misled about earlier cases. Referring to the Reedley lab, he said the prior administration had downplayed or obscured potential links to the Chinese government.
“If you recall, a similar incident in Reedley, California from a few years ago was evidently buried by the prior administration, and they said it had no connection to the CCP,” Patel said. He said his team is working to correct past intelligence assessments and determine why the public was given incomplete information.
According to Patel, the FBI has already collected more than 1,000 samples from the Las Vegas site for analysis and is coordinating with state authorities. He said the bureau will release findings once laboratory testing is complete.
The Reedley case has also drawn scrutiny from Congress. The House Select Committee on the CCP highlighted the case in a 2023 report, detailing alleged ties between the lab’s operator, Jia Bei Zhu, and Chinese state-linked enterprises. The report said Zhu previously served as a vice chairman of a PRC state-controlled company with military-civil fusion ties and later chaired another firm whose directors included an executive from a Chinese defense company.
The House report further alleged that Zhu stole American intellectual property, transferred it to China, and sold counterfeit medical test kits falsely labeled as made in the United States, while receiving more than $1 million in unexplained wire transfers from Chinese banks. The committee criticized federal agencies’ responses, particularly the Centers for Disease Control and Prevention, and questioned why the FBI initially closed its inquiry after concluding no weapons of mass destruction were present.
Patel also criticized the Biden administration’s decision to shut down the FBI’s China Initiative, the bureau’s primary program for countering Chinese espionage within academia and research institutions. He said its termination allowed CCP-linked activities to expand inside the United States.
“Who takes down an initiative against our number one adversary, the CCP,” Patel said, “when they are not only conducting counterespionage activities here in the homeland against Americans, but also overseas, and importing illegal bio pathogens to harm our way of life?” He said the Trump administration reversed course by directing the FBI to focus broadly and aggressively on the CCP without creating a new branded initiative.
Patel also pointed to recent arrests involving Chinese students and researchers in Michigan. He said federal authorities arrested three researchers connected to the University of Michigan for illegally importing biohazardous pathogens into the United States, alleging the materials were intended to undermine U.S. scientific and agricultural sectors.
The Justice Department announced in June that Yunqing Jian and Zunyong Liu were charged with conspiracy, smuggling, false statements, and visa fraud related to the importation of the fungus Fusarium graminearum, which officials described as a potential agroterrorism weapon. Additional cases followed, including guilty pleas and further charges detailed in DOJ announcements in September and November.
Bhattacharya said the administration is also tightening oversight of foreign researchers working in the United States. He noted that the NIH last year announced new restrictions barring foreign subawards, including those involving China, under NIH-funded grants, citing national security and transparency concerns.
“We need safeguards that make sure that the American investments don’t result in threats and harms to America,” Bhattacharya said, adding that past collaborations with China lacked sufficient protections.
Patel said the FBI’s renewed posture reflects a long-term commitment to countering what he described as malign CCP activity, emphasizing that the bureau will continue working with other agencies and Congress to expose threats and correct what he called past failures in protecting national security.
Original article
Comments